In This Section

NextGen Stars

The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected as AACR NextGen Stars.

Congratulations to the 2020 NextGen Stars!

Uri Ben-David, PhD

Uri Ben-David, PhD

Assistant Professor, Department of Human Molecular Genetics and Biochemistry
Tel Aviv University, Tel Aviv, Israel
Genomic evolution of cancer models: perils and opportunities
Major Symposium SY38 – Modeling Metastatic Progression in the Mouse
Tuesday, April 28, 2020, 10:30 a.m.-12:15 p.m.

Joshua J. Breunig, PhD

Joshua J. Breunig, PhD

Assistant Professor, Department of Biomedical Sciences
Cedars-Sinai Medical Center, Los Angeles, California
MADR: rapid generation of somatic mosaics with locus-specific, stably-integrated transgenic elements for generation of “personalized” mouse models and human organoid tumor models
Major Symposium SY16 – Functional Precisions Medicine in Cancer
April 26, 2020, 1-2:45 p.m.

Marios Giannakis, MD, PhD

Marios Giannakis, MD, PhD

Assistant Professor of Medicine, Medical Oncology
Dana-Farber Cancer Institute, Boston, Massachusetts
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Major Symposium SY28 – Cancer Immunometabolism
Tuesday, April 28, 2020, 1 -2:45 p.m.

Lee D. Gibbs, PhD

Lee D. Gibbs, PhD

Postdoctoral Fellow, Department of Translational Genomics
Keck School of Medicine of University of Southern California, Los Angeles, California
Spatial RNA-seq reveals intra-tumor heterogeneity and transcriptional substructure in high grade ovarian cancers
Major Symposium SY03 – From ‘Omics Data to Prognostic and Predictive Biomarkers Tuesday, April 28, 2020, 1-2:45 p.m.

Sheng Li, PhD

Sheng Li, PhD

Assistant Professor, Genomic Medicine
The Jackson Laboratory, Farmington, Connecticut
Somatic mutations drive specific, but reversible epigenetic heterogeneity states in AML
Major Symposium SY32 – Metabolism and Chromatin Deregulation in Cancer and Cancer Heterogeneity
Tuesday, April 28, 2020, 1-2:45 p.m.

Ping Mu, PhD

Ping Mu, PhD

Assistant Professor, Department of Molecular Biology
The University of Texas Southwestern Medical Center, Dallas, Texas
CHD1-Loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity
Major Symposium SY18 – Tumor Cell Plasticity and Resistance to Cancer Therapies Monday, April 27, 2020, 10:30 a.m.-12:15 p.m.

Maeve Mullooly, PhD, MPH

Maeve Mullooly, PhD, MPH

Research Fellow, Division of Population Health Sciences
Royal College of Surgeons in Ireland, Dublin, Ireland
Investigation of relationships between breast cancer risk factors and bilateral mammographic breast density asymmetry among women undergoing diagnostic image-guided breast biopsies
Advances in Diagnostics and Therapeutics ADT05 – Hybrid Technologies for Cancer
Imaging and Image-Guided Interventions
Monday, April 27, 2020, 10:30 a.m.-12:15 p.m.

Cristina Puig-Saus, PhD

Cristina Puig-Saus, PhD

Associate Project Scientist, Division of Hematology-Oncology
University of California, Los Angeles, Los Angeles, California
Landscape analysis of neoepitope-specific T cell responses to immunotherapy
Major Symposium SY26 – TCR Targeting of Mutational Neoantigens
Wednesday, April 29, 2020, 10:15 a.m.-12 p.m.

Nidhi Sahni, PhD

Nidhi Sahni, PhD

Assistant Professor, Department of Epigenetics and Molecular Carcinogenesis

The University of Texas MD Anderson Cancer Center, Smithville, Texas
Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer
Major Symposium SY17 – Colorectal Cancer Interception: Immunologic and Pharmacologic Advances
Monday, April 27, 2020, 1-2:45 p.m.

Ingunn Stromnes, PhD

Ingunn Stromnes, PhD

Assistant Professor, Department of Microbiology and Immunology
University of Minnesota, Minneapolis, Minnesota
Combination CD40 agonist and anti-PD-L1 eradicate pancreatic ductal adenocarcinoma by expanding type I dendritic cells, altering cytokine and chemokine production, and promoting intratumoral KLRG1+ tumor-specific T cells
Major Symposium SY23 – T Cells in Cancer
Sunday, April 26, 2020, 1-2:45 p.m.

Neil Vasan, MD, PhD

Neil Vasan, MD, PhD

Assistant Attending Physician
Memorial Sloan Kettering Cancer Center, New York, New York
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Advances in Organ Site Research AOS01 – Therapeutic Vulnerabilities and Resistance Mechanisms in Estrogen Receptor-Positive Breast Cancer
Wednesday, April 29, 2020, 10:15 a.m.-12 p.m.

Liling Wan, PhD

Liling Wan, PhD

Assistant Professor, Department of Cancer Biology
University of Pennsylvania, Philadelphia, Pennsylvania
Gain-of-function mutations in histone acetylation reader ENL in human cancer
Major Symposium SY12 – Next-Generation Epigenetic Drugs
Sunday, April 26, 2020, 1-2:45 p.m.